Clinical Significance of Combined Detection of Serum Tumor Markers in Diagnosis of Patients with Ovarian Cancer |
Bian, Jing
(Department of Laboratory, The First Affiliated Hospital of Zhengzhou University)
Li, Bo (The Stem Cells Research Center, Medical College of Zhengzhou University) Kou, Xian-Juan (College of Health Science, Wuhan Sports University) Liu, Tian-Zhou (Department of Laboratory, The First Affiliated Hospital of Zhengzhou University) Ming, Liang (Department of Laboratory, The First Affiliated Hospital of Zhengzhou University) |
1 | Wang WJ, Tao Z, Gu W, Sun LH (2013).Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination. Asian Pac J Cancer Prev, 14, 4369-71. DOI ScienceOn |
2 | Yin, BW, Lloyd, K (2001). Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J Biol Chem, 276, 27371-75. DOI ScienceOn |
3 | Yu D, Du K, Liu T, Chen G (2013). Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients. Int J Mol Sci, 14, 11145-56. DOI ScienceOn |
4 | Zheng CX, Zhan WH, Zhao JZ, et al (2001). The prognostic value of preoperative serum levels of CEA, CA19-9 and CA72-4 in patients with colorectal cancer. World J Gastroenterol, 7, 431-4. DOI |
5 | Bast RC Jr, Feeney M, Lazarus H, et al (1981). Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest, 68, 1331-7. DOI |
6 | Duffy MJ, Lamerz R, Haglund C, et al (2013). Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers (EGTM) 2013 guidelines update. Int J Cancer. ( Epub ahead of print) |
7 | Li J, Cheng H, Zhang P, et al (2013). Prognostic value of combined serum biomarkers in predicting outcomes in cervical cancer patients. Clin Chim Act, 11, 292-7. |
8 | Frede J, Fraser SP, Oskay-Ozcelik G, et al (2013). Ovarian cancer: Ion channel and aquaporin expression as novel targets of clinical potential. Eur J Cancer, 49, 2331-44. DOI ScienceOn |
9 | Foley OW, Rauh-Hain JA, del Carmen MG (2013). Recurrent epithelial ovarian cancer: an update on treatment. Oncology, 27, 288-94, 298. |
10 | Hall M, Gourley C, McNeish I, et al (2013). Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer, 108, 250-8. DOI ScienceOn |
11 | Mizumoto Y, Kyo S, Takakura M, Nakamura M, Inoue M (2010). Nihon Rinsho, 7, 717-9. |
12 | O’Brien TJ, Beard JB, Underwood LJ, et al (2001). The CA125 gene: An extracellular superstructure dominated by repeat sequences. Tumour Biol, 22, 348-66. DOI ScienceOn |
13 | Ruibal A, Gonzalez-Sistal A, Menendez P, Arias JI, Herranz M (2012). Only in patients with hormone-dependent breast infiltrating ductal carcinomas, CA15.3 serum levels are inversely correlated with the immunohistochemical expression of Bcl2. Clin Chim Act, 413, 1792-5. DOI ScienceOn |
14 | Radka S, Weston BS, Kieran W, et al (2013). Exploring the Glycosylation of Serum CA125. Int J Mol Sci, 14, 15636-54. DOI |
15 | Scholler N, Urban N (2007). CA125 in ovarian cancer. Biomark Med, 1, 513-23 DOI |
16 | Sisik A, Kaya M, Bas G, Basak F, Alimoglu (2013). CEA and CA19-9 are Still Valuable Markers for the Prognosis of Colorectal and Gastric Cancer Patients. Asian Pac J Cancer Prev, 14, 4289-94 DOI ScienceOn |